Literature DB >> 27602140

Expression of microRNA-30a-5p in drug-resistant and drug-sensitive ovarian cancer cell lines.

Jin Liu1, Xiaohua Wu2, Hongmei Liu3, Yijuan Liang4, Xinping Gao4, Zhihui Cai4, Weiming Wang4, Hui Zhang4.   

Abstract

The present study aimed to explore the expression of microRNA (miRNA or miR) in drug-resistant and drug-sensitive ovarian cancer cell lines, and to seek the potential therapeutic target of ovarian cancer drug-resistant mechanism in order to improve drug resistance by altering miRNA levels. The drug-resistant characteristics of SKOV3/DDP, SKOV3, COC1/DDP and COC1 cell lines were studied. The miRNAs that were differentially expressed between cisplatin-resistant cells and its parental cells in ovarian cancer were screened with a miRNA chip. The effect of miRNAs was detected, and their drug-resistant mechanism was investigated by transfection and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide methods. Among the expression screening of miRNAs, 41 mRNAs, including Homo sapiens (hsa)-miR-30a-5p and hsa-miR-34c-5p, were highly expressed in the drug-resistant cells, whereas 44 miRNAs, including hsa-miR-96-5p and hsa-miR-200c-3p, were lowly expressed. The expression levels of hsa-miR-30a-5p in two types of ovarian cancer chemotherapy-resistant cell lines were significantly higher than those in chemotherapy-sensitive cell lines, which was associated with ovarian cancer chemotherapy resistance. In conclusion, high expression of miRNA-30a-5p was able to promote cell growth and colony forming ability, and enhance cell migration and invasion. Thus, miRNA-30a-5p is expected to become a meaningful novel target for ovarian cancer resistant treatment.

Entities:  

Keywords:  drug resistance; microRNA; microRNA-30a-5p; ovarian cancer

Year:  2016        PMID: 27602140      PMCID: PMC4998657          DOI: 10.3892/ol.2016.4831

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

1.  MicroRNA expression profiles in serous ovarian carcinoma.

Authors:  Eun Ji Nam; Heejei Yoon; Sang Wun Kim; Hoguen Kim; Young Tae Kim; Jae Hoon Kim; Jae Wook Kim; Sunghoon Kim
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

2.  MiR-17-5p up-regulates YES1 to modulate the cell cycle progression and apoptosis in ovarian cancer cell lines.

Authors:  Lan Li; Li He; Jian-Li Zhao; Jing Xiao; Min Liu; Xin Li; Hua Tang
Journal:  J Cell Biochem       Date:  2015-06       Impact factor: 4.429

3.  Antitumor therapeutic and antimetastatic activity of electroporation-delivered human papillomavirus 16 E7 DNA vaccines: a possible mechanism for enhanced tumor control.

Authors:  In Hee Lee; Jae-Bok Park; Minseon Cheong; Youn Seok Choi; Daehan Park; Jeong-Im Sin
Journal:  DNA Cell Biol       Date:  2011-06-07       Impact factor: 3.311

4.  miR-200a overexpression in advanced ovarian carcinomas as a prognostic indicator.

Authors:  Cheng-Liang Zhu; Guo-Sheng Gao
Journal:  Asian Pac J Cancer Prev       Date:  2014

5.  MicroRNA signatures in human ovarian cancer.

Authors:  Marilena V Iorio; Rosa Visone; Gianpiero Di Leva; Valentina Donati; Fabio Petrocca; Patrizia Casalini; Cristian Taccioli; Stefano Volinia; Chang-Gong Liu; Hansjuerg Alder; George A Calin; Sylvie Ménard; Carlo M Croce
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

Review 6.  Ovarian cancer: strategies for overcoming resistance to chemotherapy.

Authors:  Roshan Agarwal; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2003-07       Impact factor: 60.716

7.  Role of microRNAs in drug-resistant ovarian cancer cells.

Authors:  Antonio Sorrentino; Chang-Gong Liu; Antonio Addario; Cesare Peschle; Giovanni Scambia; Cristiano Ferlini
Journal:  Gynecol Oncol       Date:  2008-09-26       Impact factor: 5.482

Review 8.  Genomic alterations as mediators of miRNA dysregulation in ovarian cancer.

Authors:  Casina W S Kan; Viive M Howell; Michael A Hahn; Deborah J Marsh
Journal:  Genes Chromosomes Cancer       Date:  2014-10-03       Impact factor: 5.006

Review 9.  Clinically relevant microRNAs in ovarian cancer.

Authors:  Shu Zhang; Zhen Lu; Anna K Unruh; Cristina Ivan; Keith A Baggerly; George A Calin; Zongfang Li; Robert C Bast; Xiao-Feng Le
Journal:  Mol Cancer Res       Date:  2014-10-10       Impact factor: 5.852

10.  FSH stimulates expression of the embryonic gene HMGA2 by downregulating let-7 in normal fimbrial epithelial cells of ovarian high-grade serous carcinomas.

Authors:  Xu-Yin Zhang; Jing-Xin Ding; Xiang Tao; Ke-Qin Hua
Journal:  Exp Ther Med       Date:  2012-02-11       Impact factor: 2.447

View more
  9 in total

1.  Expression Profile of mRNAs and miRNAs Related to the Oxidative-Stress Phenomenon in the Ishikawa Cell Line Treated Either Cisplatin or Salinomycin.

Authors:  Szymon Januszyk; Paweł Mieszczański; Hubert Lurka; Dorota Sagan; Dariusz Boroń; Beniamin Oskar Grabarek
Journal:  Biomedicines       Date:  2022-05-20

2.  Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low-dose fraction radiation.

Authors:  Lili Zhao; Shihai Liu; Donghai Liang; Tao Jiang; Xiaoyan Yan; Shengnan Zhao; Yuanwei Liu; Wei Zhao; Hongsheng Yu
Journal:  Cancer Med       Date:  2019-04-02       Impact factor: 4.452

Review 3.  Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients.

Authors:  Heidi Schwarzenbach; Peter B Gahan
Journal:  Cancer Drug Resist       Date:  2019-06-19

Review 4.  Relationship between ovarian cancer stem cells, epithelial mesenchymal transition and tumour recurrence.

Authors:  Monica Angelica Amaya Padilla; Mudra Binju; Graeme Wan; Yohan Suryo Rahmanto; Pritinder Kaur; Yu Yu
Journal:  Cancer Drug Resist       Date:  2019-12-19

5.  Bioinformatics prediction of differential miRNAs in non-small cell lung cancer.

Authors:  Kui Xiao; Shenggang Liu; Yijia Xiao; Yang Wang; Zhiruo Zhu; Yaohui Wang; Jiehan Jiang
Journal:  PLoS One       Date:  2021-07-21       Impact factor: 3.240

6.  miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples.

Authors:  Ovidiu-Leonard Braicu; Liviuta Budisan; Rares Buiga; Ancuta Jurj; Patriciu Achimas-Cadariu; Laura Ancuta Pop; Cornelia Braicu; Alexandru Irimie; Ioana Berindan-Neagoe
Journal:  Onco Targets Ther       Date:  2017-08-28       Impact factor: 4.147

Review 7.  Ancient and modern: hints of a core post-transcriptional network driving chemotherapy resistance in ovarian cancer.

Authors:  Sarah Blagden; Mai Abdel Mouti; James Chettle
Journal:  Wiley Interdiscip Rev RNA       Date:  2017-08-01       Impact factor: 9.957

8.  miR-148a-3p suppresses epithelial ovarian cancer progression primarily by targeting c-Met.

Authors:  Wen Wang; Jing Dong; Maoxiu Wang; Shujuan Yao; Xiangyu Tian; Xiujuan Cui; Shijie Fu; Shiqian Zhang
Journal:  Oncol Lett       Date:  2018-02-23       Impact factor: 2.967

9.  Bioinformatics analysis of prognostic value and prospective pathway signal of miR-30a in ovarian cancer.

Authors:  Weijia Lu; Yunyu Wu; Can Xiong Lu; Ting Zhu; Zhong Lu Ren; Zhiwu Yu
Journal:  J Ovarian Res       Date:  2020-10-01       Impact factor: 4.234

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.